SAR445877 + FOLFOX6 + Bevacizumab for Colorectal Cancer

This trial aims to determine if a new drug, SAR445877 (experimental treatment), combined with FOLFOX6 (a chemotherapy regimen) and bevacizumab (an anti-cancer drug), can be safely administered to individuals with advanced colorectal cancer that is microsatellite stable (MSS) and has spread. Researchers are identifying the right dose and assessing whether this combination can effectively treat the cancer. The trial seeks participants with advanced-stage colorectal cancer that is untreated and confirmed as MSS. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you are on systemic corticosteroids or other immunosuppressive medications, you may need to stop them before starting the trial. It's best to discuss your specific medications with the trial team.

Previous studies have shown that SAR445877 is generally safe when used alone in patients with advanced solid tumors, meaning most people did not experience severe side effects. The treatment also showed promise in fighting tumors. However, ongoing tests aim to ensure its safety and effectiveness.

FOLFOX6 and bevacizumab are already approved for treating colorectal cancer and are generally considered safe for this use.

Researchers are excited about SAR445877 for colorectal cancer because it introduces a new active ingredient that may enhance the effectiveness of existing treatments like FOLFOX6 and Bevacizumab. Unlike standard chemotherapy, which broadly targets rapidly dividing cells, SAR445877 is designed to more precisely target cancer cells, potentially leading to better outcomes and fewer side effects. This precision approach could transform the way colorectal cancer is treated by increasing the efficacy of existing regimens and reducing the burden on patients.

Studies have shown that SAR445877 shows promise as a cancer treatment. In earlier research, it helped shrink tumors in patients with advanced colorectal cancer, which starts in the colon or rectum. One study found that two patients had partial responses, with their tumors shrinking for several months. SAR445877 also performed well in lab tests on cancer resistant to other treatments. This trial will evaluate SAR445877 in combination with FOLFOX6 and bevacizumab. Although still in early stages, these signs suggest SAR445877 could be effective when used with these other drugs.¹²³⁴⁶